“China biotech is no longer just an emerging story — unlike 10 years ago — it is now a disruptive force reshaping global drug innovation,” said Yiqi Liu, senior investment analyst at Exome Asset Management LLC in New York. “The science is real, the economics are compelling, and the pipeline is starting to deliver.”
Bloomberg
Can be said of MSB as well
“China biotech is no longer just an emerging story — unlike 10...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.80 |
Change
-0.030(1.64%) |
Mkt cap ! $2.306B | |||
| Open | High | Low | Value | Volume |
| $1.80 | $1.83 | $1.76 | $11.26M | 6.310M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 24 | $1.91 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.62 | 9592 | 3 |
View Market Depth
| Last trade - 15.59pm 18/06/2025 (20 minute delay) ? |
| MSB (ASX) Chart |